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Abstract
Introduction: Tumour necrosis factor alpha (TNFa) plays an important role in the pathogenesis of rheumatoid arthritis (RA). Inflixi-
mab (Remicade) is an agent with neutralising effects on the TNFa biological activity. The aim of the study was to assess the dynam-
ics of changes in motor function of patients with RA during infliximab treatment.
Methods: Infliximab was administered at doses of 3 mg/kg in a  2-hour intravenous infusion for 14 weeks; initially, the infusions were 
given every 2 weeks, subsequently every 4 weeks. Eight women at moderately advanced or advanced stages of RA (stages IIş and IIIş 
according to Steinbrocker Staging System) hospitalised in the Rheumatology Ward of the Józef Dietl Hospital in Cracow were en-
rolled in the study. Mean serum CRP level in these patients was 3.15 mg%, and the 1-hour sedimentation rate was 55.5. The range 
of motion was evaluated using the Mechanical Joint Score (MJS) via mobility assessment in the joints of the hands, wrists, and in the 
elbow, shoulder, hip, knee and ankle joints. Grasp force of the hands was assessed by means of a  sphygmomanometer cuff, and the 
intensity of the inflammatory process, pain and joint stiffness using the questionnaires Western Ontario Mc Master University Index 
(WOMAC) and Rheumatoid Arthritis Disease Activity Index (RADAI).
Results: Statistically significant improvement in the motor function of the joints assessed using MJS and in the quality of life meas-
ured by means of RADAI and WOMAC occurred as early as after 2 weeks of the therapy. Pain was markedly alleviated and the grasp 
force of the hands significantly improved. Normalisation of the CRP concentration and the sedimentaion rate was observed. The 
most pronounced improvement of all parameters was demonstrated after the first infliximab infusion. During the subsequent weeks, 
the improvement was significantly slower. In the 14th week of treatment, a  marked exacerbation of the disease, yet not exceeding the 
pre-treatment intensity, was noted, likely due to the increased interval between the successive doses of the preparation.
Conclusions: Administration of infliximab in patients with RA induces a  quick and significant improvement in patients’ motor func-
tion; however, beneficial effects of this agent were attenuated during the subsequent phases of infliximab therapy. This effect may 
have been caused by the reduction of administration frequency of the preparation (initially every 2 weeks, then every 4 weeks). Ther-
apy-associated occurrence of infliximab-neutralising antibodies resulting in a  reduced efficacy of the treatment with this agent can-
not be excluded either.
Słowa kluczowe
reumatoidalne zapalenie stawów (RZS), TNFa, infliximab, ruchomość stawów, siła mięśniowa.
Streszczenie
Wstęp: W  patogenezie reumatoidalnego zapalenia stawów (RZS) ważną rolę odgrywa czynnik martwicy guzów alfa (TNFa). Lekiem 
neutralizującym biologiczną aktywność TNFa jest infliximab (Remicade) Celem pracy było określenie dynamiki zmian sprawności 
ruchowej pacjentów chorych na RZS w  trakcie leczenia infliximabem.
Metodyka: Infliximab podawano w  dawkach 3 mg/kg w  postaci 2 godzinnego wlewu dożylnego przez 14 tygodni; początkowo sto-
sowano infuzje co 2 tygodnie, następnie co 4 tygodnie. Grupę badawczą stanowiło 8 kobiet ze średnio zaawansowanym, lub zaawa-
nsowanym RZS (IIo i  IIIo gr wg Steinbrockera) leczonych na Oddziale Reumatologii Szpitala im J  Dietla w  Krakowie. Średnia 
wartość CRP w  surowicy tych chorych wynosiła 3,15 mg%, a  OB 55,5 po 1 godz. Zakres ruchów badano za pomocą Mechanical 
Joint Score (MJS), oceniając ruchomość w  stawach rąk, nadgarstkowych, oraz w  stawach łokciowych, barkowych, biodrowych, ko-
lanowych i  skokowych. Oceniano siłę chwytu rąk przy pomocy mankietu do pomiaru ciśnień, oraz nasilenie procesu zapalnego, ból 
i  sztywność stawów używając kwestionariuszy Western Ontario Mc Master University Index (WOMAC) oraz Rheumatoid Arthritis 
Disease Activity Index (RADAI).
Wyniki: Już po pierwszych 2 tygodniach leczenia nastąpiła istotna statystycznie poprawa sprawności ruchowej w  stawach mierzona 
za pomocą MJS, oraz jakości życia mierzona kwestionariuszami RADAI i  WOMAC. Wyraźnie zmniejszyły się dolegliwości bólowe 
i  znaczącej poprawie uległa siła chwytu rąk. Zaobserwowano normalizację wartości CRP i  OB. Największą poprawę wszystkich 
parametrów zaobserwowano po pierwszym wlewie infliximabu. W  ciągu kolejnych tygodni poprawa postępowała znacznie wolniej. 
W  14 tygodniu leczenia stwierdzono wyraźne zaostrzenie procesu chorobowego, związane prawdopodobnie z  dłuższym odstępem 
pomiędzy kolejnymi dawkami leku, nie osiągające jednak nasilenia takiego jak przed rozpoczęciem leczenia.
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Introduction
Rheumatoid arthritis (RA) is a  chron-
ic systemic disease of unknown aeti-
ology. In the course of the disease, sy-
novial hypertrophy, bone and articu-
lation cartilages damage and joint de-
formation as well as an impairment 
of joint function occur. Studies con-
ducted within the last years indicate 
an important role of cytokines, par-
ticularly of the tumour necrosis factor 
a  (TNFa), in the pathogenesis of RA. 
The cytokine is synthesised by mac-
rophages and ssynoviocytes A  and 
B  and occurs at high levels in the sy-
novial fluid and the articular synovia 
of patients with RA1,2. TNFa induces 
secretion of other cytokines, increas-
es synthesis of acute phase proteins 
and enhances fibroblasts and osteo-
clasts activity, influences the produc-
tion of adhesion proteins and angio-
genesis, and also activates the release 
of metaloproteinases by synovial cells. 
Inactivation of the TNFa diminishes 
inflammatory response and improves 
the effectiveness of RA treatment; 
and TNFa blocking agents are used 
to treat this disease in many coun-
tries1–5.
Infliximab (Remicade) is a  chimeri-
cal mouse-human monoclonal IgG an-
tibody that recognises and neutralis-
es TNFa. The drug substance forms 
complexes both with the soluble and 
the cell membrane-linked TNFa. Inf-
liximab induces cell lysis not only via 
the cytotoxic antibodies-dependent 
mechanism, but also via the comple-
ment activation6,7. It also activates cas-
pases and augments apoptosis of the 
monocytes8. Anti-TNFa therapy leads 
to a  reduction of other pro-inflam-
matory cytokines plasma activity and 
decreases the synthesis of angiogenic 
factors and acute phase proteins1,8,9. 
There are reports demonstrating that 
months-long therapy with anti-TNFa 
agents slows RA inflammation-in-
duced degradation of the articular 
structures10,11.
In our study, we attempted to deter-
mine the effects of infliximab on the 
motor function of patients with RA. 
As a  part of the study, we pursued the 
dynamics of changes in joint mobili-
ty and stiffness, muscle strength, pain 
and evaluated subjective improvement 
in the clinical status of RA patients 
treated with infliximab.
Material and methods
The study was conducted in the Józef 
Dietl Specialist Hospital in Cracow 
at the Rheumatology Ward during 
the period of January 2004 to April 
2005.
Eight female patients aged 46 to 57 
years with the diagnosis of active RA 
according to the ARA criteria were 
qualified for the infliximab treatment. 
Patients’ characteristics are presented 
in the Table 1. The patients had earlier 
been treated with methotrexate, corti-
costeroids and NSAID; however, this 
treatment did not enable the achieve-
ment of remission. Patients using oth-
er medication modifying the disease 
course within the 4 weeks preceding 
infliximab therapy initiation or who 
had infections or opportunistic infec-
tions (e.g. zoster), allergies, neoplas-
tic diseases or other serious concomi-
tant diseases were excluded from the 
study. Infliximab was given at dose of 
3 mg/kg body weight in a  2-hour in-
travenous infusion according to the 
regime: 0 – 2nd – 6th – 14th week. As-
sessment procedures were performed 
prior to patient’s qualification for the 
therapy and immediately before each 
infliximab infusion. During the inflix-
imab therapy, the patients were not 
receiving other diseases modifying the 
RA course.
Evaluated parameters
Assessment of the motion range in the 
joints was performed according to The 
Mechanical Joint Score (MJS), which 
is a  clinical indicator of joint damage 
in RA and enables quick evaluation of 
the metacarpophalangeal, interphalan-
geal, wrist, elbow, shoulder, hip, knee, 
ankle and metatarsal joints mobility. 
According to the MJS, a  total of 34 
points indicates mobility restriction in 
all evaluated articulations12.
Grasp force of the hands was mea-
sured using a  sphygmomanometer 
cuff that was pumped to 100 mmHg 
and the patient was subsequent-
Wnioski: Zastosowanie infliximabu u  chorych na RZS powoduje szybką i  znaczącą poprawę sprawności ruchowej tych chorych, 
jednak korzystne efekty tego leku uległy zmniejszeniu w  następnych etapach leczenia infliximabem. Przyczyn tego zjawiska można 
upatrywać w  zmniejszeniu częstości podawania leku (w początkowym okresie co 2 tygodnie, potem co 4 tygodnie). Niewykluczone 
jest również, że w  trakcie stosowanego leczenia pojawiły się przeciwciała neutralizujące infliximab i  na tej drodze doszło do zmniej-
szenia skuteczności działania tego leku.
table 1
Clinical characteristics of patients qualified for the therapy with Remicade 
(n=8)
Parameters Mean Range
Age (years) 44,5 22–54
Sex:
male
female
0
8
Body weight (kg) 60,25 47–74
Disease duration (years) 5,75 1–11
RA stage (according to Steinbrockera) (number of patients)
grup I
grup II
grup III
grup IV
0
5
3
0
Waaler-Rose reaction
negative:
positive:
5
3
Sedimentation rate after 1 hour (mm/h) 55,5 26–114
C-reactive protein (mg/dl) 3,15 0,55–6,01

ly asked to squeeze it with possibly 
greatest force. Such trial was repeated 
3 times and the average value was re-
ported; the whole procedure was per-
formed bilaterally for comparison.
Patients motor function, pain and 
stiffness were measured using the 
modified WOMAC (Western Ontar-
io and MacMaster Universities Index) 
questionnaire. WOMAC was used for 
the purpose of evaluation of the joints, 
although it is a  questionnaire used for 
the assessment of a  degenerative dis-
ease. It consists of 24 questions divid-
ed into 3 groups; 5 referring to pain, 
2 referring to stiffness and 17 refer-
ring to motor function13.
The patients assessed the disease ac-
tivity by means of the RADAI (Rheu-
matoid Arthritis Disease Activity In-
dex), which consists of a  point-scale 
that can be performed by the patient 
herself. The index evaluates the inten-
sity of the inflammatory state, the pain 
and joint stiffness. It has been shown 
that this scale largely correlates with 
signs of the disease and laboratory in-
dices of disease activity14.
The patients enrolled in the study 
were given Remicade at dose of 3 mg/
kg body weight in a  2-hour intrave-
nous infusion according to the follow-
ing regime: 0 – 2nd – 6th – 14th week. 
The patients were evaluated using the 
above methods prior to each infusion 
of Remicade, while the sedimenta-
tion rate and the CRP were also con-
trolled.
The Friedman test / the Friedman 
two-way ANOVA by ranks / the two-
way analysis on ranks, a  non-para-
metric equivalent of repeated mea-
sures one-way analysis of variance, 
was used.
Results
An improvement in the motor func-
tion and general status was observed 
in all patients receiving infliximab. 
The significant and the most pro-
nounced remission was observed fol-
lowing the administration of the first 
dose of the preparation. A  significant 
reduction of joint mobility restriction, 
increase in hand grasp force, improve-
ment in motor function, alleviation 
of pain and stiffness as well as dimin-
ished patient-assessed disease activity 
Figure 1
Changes in joint motion range restrictions at initial evaluation and during subsequent 
weeks of infliximab infusions – MJS questionnaire results. Mean ± SEM of the 
assessments in 8 patients, statistically significant (p<0.05) mobility improvement as 
compared to the pre-treatment value is indicated by an asterisk.
Figure 2
Changes in right hand grasp force at initial evaluation and during subsequent weeks 
of infliximab infusions. Mean ± SEM of the assessments in 8 patients, statistically 
significant (p<0.05) improvement in the right hand grasp force as compared to the 
pre-treatment value is indicated by an asterisk.
Figure 3
Changes in left hand grasp force at initial evaluation and during subsequent weeks 
of infliximab infusions. Mean ± SEM of the assessments in 8 patients, statistically 
significant (p<0.05) improvement in the left hand grasp force as compared to the pre-
treatment value is indicated by an asterisk.
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were observed. Similar changes were 
observed in the sedimentation rate 
and the CRP results (Figures 1–9).
The greatest increase in the mobili-
ty of hand articulations was observed 
following the first infliximab admin-
istration, which occurred in all pa-
tients. Further, gradual improvement 
was observed following the next infu-
sions (Figure 1). The increased joint 
mobility was due to a  significant at-
tenuation of joint pain and oedema. 
Only in one patient, was a  slight mo-
bility reduction observed before the 
infusion III and IV as compared to the 
improvement observed during the ini-
tial phase of treatment.
A significant increase in hand grasp 
force occurred following the first ad-
ministration of the agent and was ob-
served in all patients. Such increase 
tendency persisted until the 6th week; 
however, immediately before the infu-
sion IV, a  decrease in the grasp force 
was noted in all patients (Figures 2 
and 3).
The motor function assessed by the 
patients using the WOMAC invento-
ry was significantly improved follow-
ing the first infusion. After the sub-
sequent drug administrations, the im-
provement was insignificant, and the 
motor function worsened immediately 
before the infusion IV in comparison 
to the preceding evaluation (Figure 4). 
Only in one patient, did a  reduction 
in the improvement of motor function 
occur also before the infusion III.
Subjectively, pain experience in the 
patients was best alleviated following 
the infusion I  of infliximab (Figure 5). 
After subsequent infusions, the pain 
was slightly increased. Immediately 
before the infusion IV, marked pain 
occurred that was reported by all pa-
tients.
The greatest reduction in joint stiff-
ness occurred during the first phase 
of therapy (before the second inflix-
imab infusion) in all patients and was 
slightly improving during the subse-
quent therapy (Figure 6).
During the infliximab therapy, the 
patients experienced the most pro-
nounced decrease in disease activi-
ty following the first infusion, as ex-
pressed by the RADAI questionnaire 
self-reported results. Following subse-
quent drug administrations, they re-
Figure 4
Changes in motor functioning at initial evaluation and during subsequent weeks 
of infliximab infusions – WOMAC questionnaire results. Mean ± SEM of the 
assessments in 8 patients, statistically significant (p<0.05) improvement in 
functioning as compared to the pre-treatment value is indicated by an asterisk.
Figure 5
Changes in pain intensity at initial evaluation and during subsequent weeks 
of infliximab infusions – WOMAC questionnaire results. Mean ± SEM of the 
assessments in 8 patients, statistically significant (p<0.05) reduction in pain 
experience intensity as compared to the pre-treatment value is indicated by an 
asterisk.
Figure 6
Changes in stiffness intensity at initial evaluation and during subsequent weeks 
of infliximab infusions – WOMAC questionnaire results. Mean ± SEM of the 
assessments in 8 patients, statistically significant (p<0.05) reduction in stiffness as 
compared to the pre-treatment value is indicated by an asterisk.
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ported an insignificant exacerbation 
of the disease (Figure 7). Only one pa-
tient assessed disease activity as lower 
following each infusion.
The sedimentation rate and the 
CRP were highly significantly de-
creased following the infusion I  of 
infliximab. After subsequent adminis-
trations of the preparation, a  slight 
increase in these values was observed 
(Figures 8 and 9).
Blood pressure fluctuations prior 
to or immediately after the infusion 
were observed as undesirable effects. 
They did not require any intervention 
or – in cases of greater fluctuations – 
required postponing the infusion by 
24 hours. During the therapy, upper 
respiratory tract infections requiring 
treatment with antibiotics and post-
poning the infusions occurred several 
times in some patients. One patient re-
ported transient nausea and dyspnoea 
at night that, however, did not require 
any intervention (Table 2).
In one, 55-year old patient, who has 
been suffering from RA, stage II for 
8 years, severe anaphylactic reaction 
started to develop during the fourth 
Remicade infusion, which required 
immediate withdrawal of drug admin-
istration, introduction of appropriate 
therapy and – as a  consequence – ex-
clusion of the patient from the study. 
This patient was not included in the 
analysis of the data presented in this 
study (Table 2).
Discussion
Introduction of monoclonal anti-
TNFa antibodies, such as infliximab, 
provides new possibilities for the im-
provement of patients’ physical agil-
ity. During the 16 weeks of the thera-
py, a  significant improvement in pa-
tients’ motor function, increased mo-
tion range in the joints, increased 
grasp force and alleviation of pain 
and stiffness, as compared to the sta-
tus preceding the therapy, were ob-
served in the patients. Concurrently, 
reduction in inflammatory markers of 
RA activity such as the sedimentation 
rate and CRP were demonstrated, as 
compared to the values obtained pri-
or to Remicade treatment.
An improvement in the motor func-
tion similar to that observed in our 
Figure 7
Changes in disease activity at initial evaluation and during subsequent weeks of 
infliximab infusions – RADAI questionnaire results. Mean ± SEM of the assessments 
in 8 patients, statistically significant (p<0.05) subjective improvement in patient’s 
status as compared to the pre-treatment value is indicated by an asterisk.
Figure 8
Sedimentation rate results at initial evaluation and during subsequent weeks of 
infliximab infusions. Mean ± SEM of the assessments in 8 patients, statistically 
significant (p<0.05) reduction in the sedimentation rate as compared to the pre-
treatment value is indicated by an asterisk.
Figure 9
CRP results at initial evaluation and during subsequent weeks of infliximab infusions. 
Mean ± SEM of the assessments in 8 patients, statistically significant (p<0.05) 
reduction in the CRP level as compared to the pre-treatment value is indicated by an 
asterisk.
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study during infliximab therapy was 
reported in other studies3,4,11,15.
Beneficial effects of infliximab use 
were most pronounced after the first 
administration of this agent and were 
maintained, not uniformly, follow-
ing subsequent infusions. Around the 
14th week, a  reduction in infliximab 
efficacy was reported in the patients 
receiving this preparation, manifest-
ed as worsening of the measured pa-
rameters (including hand grasp force, 
motor function, self-reported disease 
activity, and laboratory indices – the 
sedimentation rate and CRP) in com-
parison to the values of these param-
eters determined in the preceding 
evaluation. This reduction in inflix-
imab effectiveness could be attribut-
ed to the prolongation of intervals 
between successive infusions from 4 
to 8 weeks. Such tendency was also 
observed in multi-centre studies15–17. 
The observed “exacerbation”, howev-
er, did not induce deterioration of pa-
tients’ general status, as compared to 
the pre-treatment state. In American 
studies, it was demonstrated that re-
ducing the frequency of infusions to 
one infusion every 2 weeks, instead of 
weekly infusions, can induce marked 
deterioration of the health status of 
patients treated with this preparation, 
whereas incresing the frequency of in-
fusions is a  more efficacious manage-
ment method than increasing the dose 
of infliximab18. It cannot be exclud-
ed that infliximab efficacy reduction 
results from the reaction of neutrali-
sation of this preparation by the an-
tibodies synthesised by the organism 
and directed against the anti-TNF. In 
such a  situation, antibodies inhibit-
ing infliximab would prevent its ther-
apeutic effects. It is a  very likely ex-
planation, as recently published data 
indicate that the TNFa serum lev-
el in patients with RA, who did not 
demonstrate improvement after inf-
table 2
Undesirable effects during infliximab therapy (n=8)
Undesirable effect Number of patients with symptoms
Upper respiratory tract infection 5
Arterial blood pressure fluctuations 4
Anaphylactic reaction 1
Dyspnoea 1
Nausea 1
liximab use, was several-fold higher 
than in RA patients, who beneficial-
ly responded to the therapy with this 
agent18.
Infliximab infusions are well tolerat-
ed. The most frequently observed un-
desirable effects were upper respirato-
ry tract infections. This causative ef-
fect may result from the role of TNFa 
in the human immune system19,20. 
Therefore, TNFa blockers must not 
be used in patients with severe recur-
ring infections (e.g. fungal), and the 
risk of latent tuberculosis should be 
considered prior to the treatment19. 
There are also reports on the occur-
rence of sepsis, atypical mycobacteri-
al infections, viral and fungal infec-
tions an demyelination syndromes and 
aplastic anaemia. Blood pressure fluc-
tuations occurring in some patients re-
ceiving Remicade were not clinically 
significant. Besides, they occurred in 
patients, who had formerly been di-
agnosed with arterial hypertension; 
therefore, taking infliximab may not 
necessarily be associated with blood 
pressure rises. Transient dyspnoea and 
nausea were short-term, temporary re-
actions in one patient treated with inf-
liximab, whereas in other reports (e.g. 
the ATTRACT trial), it was actually 
nausea and headache that were most 
frequently present15.
It is likely that already in close fu-
ture, new TNFa inhibitors – more ef-
fective, better tolerated and less im-
munogenic than the current prepara-
tions – will be used clinically. In the 
United States and European coun-
tries other than Poland, other forms of 
anti-cytokine therapy for RA are au-
thorised for marketing, such as human 
anti-TNFa antibody (Adalimumab) 
and soluble IL–1 receptor (Anakinra) 
– a  recombinant human protein. Cur-
rently, many forms of biological ther-
apy based on small-molecule proteins 
inhibiting both the induction of pro-
inflammatory cytokines and the lym-
phocytes activation signals are being 
evaluated in clinical trials22.
To summarise, it should be stated 
that infliximab constitutes a  signifi-
cant breakthrough and progress in the 
therapy of RA. This agent significantly 
improves patients’ functioning reduc-
ing the ailments and manifestations of 
the inflammatory process. TNFa in-
activation at an early RA stage might 
allow complete inhibition of the dis-
ease development and maintenance of 
structural and functional integrity of 
the motor system.
Conclusions
1. During the period following the 
first administration of infliximab, 
there was an improvement in mo-
tor function of all treated patients, 
as expressed by reduced pain and 
joint stiffness, improved hand 
grasp force and subjectively expe-
rienced improvement in the quali-
ty of life.
2. Beneficial effects of infliximab 
were attenuated during the ther-
apy with this agent; however, de-
spite this fact, the assessed param-
eters did not reach the pre-treat-
ment intensity.
3. Decreasing infliximab efficacy oc-
curring during the therapy may 
have resulted from the prolonga-
tion of the inter-infusion interval.
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